Becton Dickinson & Co.
BDX
ISIN null / Valor 912061
Becton Dickinson & Co.
UMushroom community rating:
About company
Becton Dickinson & Co. is a leading global medical technology company focused on improving medical discovery, diagnostics, and healthcare delivery. With a workforce of 75,000 employees, the company develops innovative technology, services, and solutions to enhance clinical therapy, improve clinical processes, and advance diagnostics and therapeutics. BD has a presence in nearly every country and collaborates with organizations worldwide to address global health challenges. The company's acquisition of CareFusion in 2015 expanded its expertise in reducing medication errors and preventing healthcare-associated infections. BD's Life Sciences segment offers solutions for infectious disease and cancer, from discovery to diagnosis, to advance scientific and clinical outcomes.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (19.10.2025):
Becton Dickinson & Co. reported strong financial results for the third quarter of fiscal 2025, demonstrating significant revenue growth, increased earnings per share, and improved margins. The company also raised its full-year EPS guidance and advanced its share buyback program, reflecting confidence in continued growth and operational excellence.
Revenue Growth
Becton Dickinson & Co. achieved a revenue of $5.5 billion in Q3 Fiscal 2025, marking a 10.4% increase as reported, an 8.5% adjusted foreign currency neutral growth, and a 3.0% organic growth.
Earnings Per Share
The company’s GAAP diluted earnings per share rose to $2.00, while adjusted diluted EPS increased to $3.68, representing growth of 19.0% and 5.1% respectively.
Margin Improvement
Becton Dickinson & Co. saw its GAAP gross margin improve by 160 basis points and adjusted gross margin by 50 basis points, driven by the BD Excellence initiative.
EPS Guidance Raised
The company raised its full-year adjusted diluted EPS guidance to a range of $14.30 to $14.45, reflecting an $0.18 increase to a 9.4% growth midpoint, while reaffirming its organic revenue growth expectations for the full year.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
55239 M
Market cap (USD)
3,000,610
Daily traded volume (Shares)
227.8 / 225.05
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
